miR-328 mediates a metabolic shift in colon cancer cells by targeting SLC2A1/GLUT1

S. Santasusagna1 · I. Moreno2 · A. Navarro1 · C. Muñoz1 · F. Martinez2 · R. Hernández2 · J. J. Castellano1 · M. Monzo1,3

Received: 20 December 2017 / Accepted: 9 January 2018 / Published online: 26 January 2018 © The Author(s) 2018. This article is an open access publication

Abstract

Purpose Increasing evidence shows that altered metabolism is a critical hallmark in colon cancer. There is a strong need to explore the molecular mechanisms underlying cancer metabolism. Whether the aberrant expression of microRNAs contributes to cancer metabolism is not fully understood. miR-328 is a putative potential target of SLC2A1, but the regulating mechanism between them remains unknown. We have examined whether miR-328 directly regulates SLC2A1/GLUT1 expression in colon cancer cells.

Methods We performed in silico bioinformatic analyses to identify miR-328-mediated molecular pathways and targets. We also performed luciferase assays and western blot analyses in LOVO and SW480 colon cancer cell lines. In addition, we assessed miR-328 expression in 47 paired tumor and normal tissue specimens from resected colon cancer patients.

Results Luciferase reporter assays showed that miR-328 directly targeted SLC2A1 3′-untranslated region (UTR), with a significant decrease in luciferase activity in both LOVO and SW480 cell lines. These results were validated by western blot. miR-328 expression was significantly downregulated in tumor tissue compared with paired normal tissue.

Conclusions Our results show that miR-328 targets SLC2A1/GLUT1. We suggest that miR-328 may be involved in the orchestration of the Warburg effect in colon cancer cells. Furthermore, miR-328 expression is reduced in colon cancer patients and thus inversely correlates with the classically reported upregulated SLC2A1/GLUT1 expression in tumors.

Keywords SLC2A1 · GLUT1 · miR-328 · Colon cancer · Glycolysis

Introduction

Colorectal cancer is the third most common cancer worldwide in both males and females and represents the second and the third cause of cancer death in males and females, respectively [1], making it a significant health burden. The vast majority of colorectal cancer cases are sporadic and usually progress from a benign polyp to a malignant adenocarcinoma while cells accumulate a series of genetic and epigenetic changes [2]. For example, mutations in KRAS predict a failure to respond to EGFR inhibitors [3].
It is well known that the metabolism of cancer cells is significantly different from that of normally differentiated cells [4]. Cancer cells preferentially use aerobic glycolysis to metabolize glucose, which is a less efficient pathway than mitochondrial oxidative phosphorylation, the main metabolic pathway used by normal cells. This different metabolism, termed the Warburg effect, is characterized by increased glycolysis and lactate production [5], which is one of the main hallmarks of cancer and could be the result of adaptations designed to maintain the continuous proliferation of cancer cells. In this malignant scenario, one of the earliest mechanisms that is upregulated during oncogenesis is the uniport protein glucose transporter 1 (GLUT1), which is a pivotal rate-limiting element in the transport of glucose in cancer cells and is responsible for increasing their glucose uptake [6]. GLUT1 deregulation results in an increased glucose uptake into the cytoplasm of tumor cells [7]. GLUT1 has found to be overexpressed in various cancers, such as esophageal squamous cell carcinoma [8], gastric carcinoma [9] and colon cancer (CC) [10, 11], and is significantly associated with worse prognosis [11]. In addition, a recent meta-analysis found that GLUT1 expression could be a promising prognostic and therapeutic target in solid tumors [6].

Recently, a number of microRNAs (miRNAs) were identified as important natural regulators of metabolism [12, 13]. For example, in renal cell carcinoma, miR-1291 induces cell proliferation, migration and invasion by targeting solute carrier family 2 member 1 (SLC2A1), which encodes GLUT1 [14]. In addition, miR-124 inhibits proliferation, glycolysis, and energy metabolism, by targeting AKT-GLUT1/HKII in non-small cell lung cancer cells [15]. Several studies have reported that miR-328 is dysregulated in numerous human cancers, thus compromising metabolic and non-metabolic pathways [16–21]. In a previous study by our group, miR-328 was present in exosomes isolated from the tumor-draining vein of CC patients and its expression was associated with liver metastases [22], leading us to speculate that miR-328 could play a role in the disruption of the metabolic pathway regulated by GLUT1 by directly binding to its 3′-UTR. However, the direct function of miR-328 in CC cells has not been examined. In the present study, we have analyzed the expression levels of miR-328 in a cohort of surgical CC patients to evaluate the relationship between miR-328 expression and its potential target SLC2A1.

Methods

Cell culture

Two human CC cell lines, LOVO (ATCC® CCL-229™) and SW480 (ATCC® CCL-228™), were provided by American Type Culture Collection (Manassas, USA). Both cell lines were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (Life Technologies, Carlsbad, CA, USA) with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO, USA) at 37°C with 5% CO2.

miRNA target prediction

Bioinformatics prediction of target genes and miRNA binding sites was performed using a combination of TargetScan version 5.1 (http://www.targetscan.com), miRanda August 2010 release (http://www.microrna.org), mirDB April 2009 (www.mirdb.org) and Tarbase (http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=tarbase/index). To obtain a reliable miRNA target prediction, we used the algorithm mirSVR for scoring and ranking the efficiency of miRNA target sites, including both target site information and contextual features [23]. In addition, phastCons score was used to study the target site conservation of nucleotide positions across multiple vertebrates [24].

miRNA transfection

One day before transfection, LOVO (8 × 10^5) and SW480 (5 × 10^5) cells were seeded in 6-well plates in RPMI media (Life Technologies) overnight. The following day, media were removed and cells were transfected with 50 ng of the pre-miRNA or pre-miR-Negative Control#1 (Life Technologies) using Lipofectamine 2000 in Opti-mem media (Life Technologies) overnight. The following day, media were removed and cells were transfected with 50 ng of the pre-miRNA or pre-miR-Negative Control#1 (Life Technologies) using Lipofectamine 2000 in Opti-mem media (Life Technologies) according to the manufacturer’s protocol. After 6 h transfection, the transfection reagent was replaced with complete RPMI media (Life Technologies). Cells were harvested for other experiments at 24 h after transfection. Transfection efficiency was monitored by qPCR.

Luciferase assay

To validate the potential target genes identified, a Luciferase assay was performed in LOVO and SW480 cells using a modified vector with the 3′UTR region of SLC2A1 gene (pMirTarget-SLC2A1-3′-UTR; accession number: 006516) obtained from Origene Technologies Inc. (Rockville, MD, USA). The Luciferase activity was measured 24 h after transfection with the Promega Dual Luciferase Reporter Assay System (Promega, Madison, WI, USA) in a luminometer Versa Max Microplate Reader. Each experiment was performed at least three times. The effect of the miR-328 in the Luciferase assay was then confirmed by western blot.
Western blot

Western blot analysis was performed in LOVO and SW480 cells using the following primary antibodies: GLUT1 (21829-1-AP, Proteintech) and α-tubulin (T 6074, Sigma-Aldrich). Briefly, the cell pellet was mixed with LDS sample buffer (Life Technologies) and sample reducing agent (Life Technologies), according to the manufacturer’s protocol. Proteins extracted were loaded onto a SDS-PAGE (Novex 4–12% Bis–Tris gel, Life Technologies), transferred to a nitrocellulose membrane by iBlot (Life Technologies), and blocked 1 h with 1× TBST buffer (Fisher Scientific) with 5% w/v nonfat dry milk. The membranes were incubated in blocking buffer at 4 °C overnight with primary antibody against GLUT1 (1:1000) or 1 h at room temperature for α-tubulin (1:3000). Subsequently, the membranes were washed three times with Tris-buffered saline with Tween-20 (TBST) and incubated 1 h with secondary antibodies (1:5000; anti-rabbit sc-2004, Santa Cruz Biotechnology; or 1:3000; anti-mouse A9044, Sigma-Aldrich). The signal was obtained using the Novex ECL Chemiluminescent Substrate Reagent kit (WP 20005, Invitrogen) and the images were developed and quantified using the Chemidoc System (Bio-Rad).

Patient samples

From August 2009 to August 2013, samples were obtained from 47 patients with stage I to III CC who underwent surgical resection at the Municipal Hospital of Badalona. All 47 patients underwent a complete history and physical examination.

Approval for the study was obtained from the institutional review board of the hospital, and signed informed consent was obtained from all patients and controls in accordance with the Declaration of Helsinki.

For all 47 patients, we obtained tumor tissue and paired normal tissue. Normal tissue was obtained from the area of the colon farthest from the tumor. Both tumor and normal tissue samples were analyzed and confirmed by a pathologist and frozen at − 80 °C for further use.

RNA extraction and miRNA quantification

Total RNA was extracted from fresh tumor and paired normal tissue using Trizol total RNA isolation reagent (Invitrogen) according to the manufacturer’s protocol. miRNA detection was performed using commercial assays (TaqMan MicroRNA assays, Life Technologies) for miR-328 (assay ID: 000543, Life Technologies), in the 7500 Sequence Detection System (Life Technologies). The appropriate negative controls were also run in each reaction. Relative quantification was calculated using the formula $2^{-\Delta\Delta Ct}$. Normalization was performed with miR-191.

Statistical analyses

Statistical analyses were performed with SPSS 22 (SPSS Inc, Chicago, IL, USA). In vitro experiments were repeated on at least three biological replicates. Data are presented as the mean ± SEM and analyzed using paired two-tailed Student’s $t$ test, using Prism software version 7.0 (GraphPad software). Differences were considered significant where $p \leq 0.05$.

Results

miR-328 targets SLC2A1

Bioinformatic analysis suggested that SLC2A1 could be a potential target of miR-328. Tarbase showed that the inhibition of SLC2A1 in Homo sapiens is partially mediated by miR-328 in two target sites that are dependent on additional non-sequence-specific context features. These SLC2A1 target sites for hsa-miR-328 are located in the 592 and 635 nucleotide positions of the 5′ gene sequence. Their mirSVR scores are −0.2195 and −0.4210, respectively, indicating that miR-328 can potentially bind to its target gene SLC2A1, especially in the 635 position, which has a more negative mirSVR score. phastCons scores for the 592 and 635 nucleotide positions suggest that both show a high conservation rate across vertebrates (0.7569 and 0.7177, respectively) (Fig. 1).

miR-328 directly regulates SLC2A1 in CC cells

To demonstrate the direct interactions between miR-328 and SLC2A1-3′UTR, a construct of this region was cloned into the pMir-Target plasmid downstream of a luciferase reporter gene (Fig. 1). A significant decrease was observed in luciferase activity in cells transfected with pMirTarget-SLC2A1 construct when treated with 100 nM pre-miR-328 relative to the same concentration of a pre-miR-Negative Control: 48.6% in LOVO ($p < 0.0001$) and 20.2% in SW480 ($p = 0.01$) (Fig. 2). There was no significant difference between cells transfected with the target constructs alone. This provides strong evidence of a direct molecular binding interaction between miR-328 and the 3′UTRs of SLC2A1, indicating that this gene could be a novel direct target of miR-328.

Western blot was carried out to determine if changes in miR-328 levels correlated with changes in SLC2A1-encoded protein levels, GLUT1. The results showed that
protein levels of GLUT1 were reduced in cells transfected with pre-miR-328 compared to cells treated with the pre-miR-Negative Control: LOVO \( (p = 0.03) \); SW480 \( (p = 0.04) \) (Fig. 3). Taken together, these data indicate that miR-328 upregulation may contribute to the inhibition of GLUT1 in CC cells.

**miR-328 expression in patient samples**

Forty-seven patients were included in the study. Median age was 73 years, and 29 (62%) were males. Thirty-three patients had stage I–II disease and 14 had stage III. Mean follow-up was 45.2 months (range 26.4–63.8) (Table 1).
Median miR-328 expression in tumor and normal tissue was −0.3838 and −0.0349, respectively. miR-328 was expressed at lower levels in tumor than in paired normal tissue \( (p < 0.0001) \) (Fig. 4).

**Discussion**

In the recent years, accumulating evidence demonstrating the critical role of a large number of miRNAs as cancer regulators [25] indicate that it is crucial to understand the molecular mechanisms of miRNAs and their potential as therapeutic targets. To understand the potential effect of miR-328 on CC cells, we performed a target prediction analysis and luciferase reporter assays in CC cell lines treated with and without pre-miR-328. Our findings confirmed that miR-328 directly targets SLC2A1 in LOVO and SW480 cells, resulting in decreased levels of GLUT1 protein. Moreover, miR-328 expression was significantly lower in tumor than in normal tissue from CC patients.

Tumor tissue is characterized by a high glucose uptake, mainly via GLUT1 [26], which is why a miR-328-mediated reduction of GLUT1, an important glucose transport protein, could compromise tumor survival.

Our results are in line with previous studies showing that miR-328 modulates both metabolic and non-metabolic pathways. miR-328 suppresses the survival of cancer cells by targeting PLCE1 in esophageal cancer [16], inhibits epithelial-to-mesenchymal transition in renal tubular cells by targeting CD44 [17, 27], and regulates cell invasion and proliferation in glioma cells by targeting TGFβ1 [18] and in melanoma cells by targeting TGFβ2 [19]. In addition, miR-328 regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells, resulting in increased chemosensitivity [20, 21]. In line with these results, a study focused on miR-328 and cancer stem cell properties suggested that miR-328 downregulation correlated with more invasive and tumorigenic phenotypes in vitro [28].
Recent studies have shown that some miRNAs secreted in the microenvironment by the tumor and niche cells could play an active role in modulating the pre-metastatic niche and subsequent metastatic progression. For example, in breast cancer, tumor-secreted miR-122 reprograms glucose metabolism in the pre-metastatic niche by inhibiting the glycolytic enzyme pyruvate kinase M2 (PKM2) [29], while in brain cancer, astrocyte-derived miR-19a secreted by the niche cells induces the loss of PTEN in tumor cells [30]. In both cases, the authors suggest that glucose is increased in the surrounding stroma. We can thus speculate that together with other accumulated metabolic molecules, the increased glucose represents a feed of nutrients and energy for the anabolic pathways required for the growth of the cancer cells when they arrive at the pre-metastatic niche.

Our findings indicate that changes in miR-328 levels correlate with changes in the levels of GLUT1, an SLC2A1-encoded protein, which has been confirmed by western blot analysis. As a result of this direct interaction between SLC2A1 and miR-328, when miR-328 levels are increased in cells transfected with its pre-miRNA, glucose uptake becomes reduced due to an inhibition of the glucose carrier GLUT1, leading to decreased glucose transport. Taken together with our previous findings that miR-328 expression in exosomes isolated from the tumor-draining vein of CC patients was associated with liver metastases [22] as well as previous studies reporting increased stromal glucose [29, 30], the results of the present study lead us to suggest that aberrant expression of miR-328 can modulate the metabolic environment in order to induce a pre-metastatic niche. Low levels of miR-328 in the tumor could allow an increase in GLUT1-mediated glucose uptake to support tumor growth while the miR-328 secreted by the cancer cells could inhibit the glucose uptake of distant stromal niche cells, resulting in stromal glucose accumulation and hence metastatic colonization.

In conclusion, to the best of our knowledge, our study is the first to demonstrate that miR-328 is potentially able to inhibit SLC2A1 and consequently regulate GLUT1-mediated glycolytic activity in cancer cells. Further exploration of the biological mechanisms underlying this interaction is warranted to evaluate the potential of miR-328 as a therapeutic target in CC.

Acknowledgements The authors thank Renée Grupp for assistance in drafting the manuscript.

Funding This work was supported by a grant from Servei de Donació del Cos a la Ciència (Body Donation Service) of the University of Barcelona. SS and JJC are APIF fellows of the University of Barcelona. Neither of these funding bodies had a role in the design and conduct of

---

**Table 1** Patient characteristics

| Characteristics                          | N (%) |
|------------------------------------------|-------|
| Sex                                      |       |
| Male                                     | 29 (62) |
| Female                                   | 18 (38) |
| Median age                               | 73    |
| CEA levels                               |       |
| ≤ 5                                      | 31 (66) |
| > 5                                      | 16 (34) |
| C 19.9 levels                            |       |
| ≤ 37                                     | 43 (92) |
| > 37                                     | 4 (8)   |
| Tumor location                           |       |
| Left colon                               | 23 (49) |
| Right colon                              | 24 (51) |
| Tumor size (cm)                          |       |
| ≤ 5                                      | 34 (72) |
| > 5                                      | 12 (26) |
| Unknown                                  | 1 (2)   |
| Histological type                        |       |
| Well differentiated                      | 42 (89) |
| Poorly differentiated                    | 5 (11)  |
| Preexistent polyp                        |       |
| Absent                                   | 35 (75) |
| Present                                  | 12 (25) |
| Perilymphatic invasion                   |       |
| Absent                                   | 44 (94) |
| Present                                  | 2 (4)   |
| Unknown                                  | 1 (2)   |
| TNM stage                                |       |
| I–II                                     | 33 (70) |
| III                                      | 14 (30) |
| Adjuvant treatment                       |       |
| Fluoropyrimidines                        | 25 (53) |
| None                                     | 22 (47) |
| Relapsed                                 |       |
| Yes                                      | 14 (30) |
| No                                       | 33 (70) |

CEA carcinoma embryonic antigen, TNM tumor, nodule, metastasis

---

**Fig. 4** miR-328 expression in paired tumor and normal tissue samples from CC patients
Compliance with ethical standards

Conflict of interest The authors declare no conflicts of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.
2. Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer J. 2012;18(3):244.
3. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62.
4. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13(6):472–82.
5. Warburg O. On the origin of cancer. Science. 1956;123(3191):309–14.
6. Wang J, Ye C, Chen C, Xiong H, Xie B, Zhou J, et al. Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(10):16875.
7. Szablewski L. Expression of glucose transporters in cancers. BBA Rev Cancer. 2013;1835(2):164–9.
8. Tohma T, Okazumi S, Makino H, Cho A, Mochizuki R, Shuto K, et al. Overexpression of glucose transporter 1 in esophageal squamous cell carcinomas: a marker for poor prognosis. Dis Esophagus. 2005;18(3):185–9.
9. Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, et al. MicroRNA-328 functions as a biomarker for recurrence of early gastric cancer (EGC) after endoscopic submucosal dissection (ESD) by modeling miRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Br J Cancer. 2013;106(7):1411–9.
10. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, et al. Glut1 glucose transporter expression in colon adenocarcinoma. Cancer. 1998;83(1):34–40.
11. Feng W, Cui G, Tang C-W, Zhang X-L, Dai C, Xu Y-Q, et al. Role of glucose metabolism related gene GLUT1 in the occurrence and prognosis of colorectal cancer. Oncotarget. 2017;8(34):356850.
12. Rottiers V, Näär AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012;13(4):239–50.
13. Wilfred BR, Wang W-X, Nelson PT. Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol Genet Metab. 2007;91(3):209–17.
14. Yamasaki T, Seki N, Yoshino H, Itesako T, Yamada Y, Tatarano S, et al. Tumor-suppressive microRNA-1291 directly regulates glucose transporter 1 in renal cell carcinoma. Cancer Sci. 2013;104(11):1411–9.
15. Zhao X, Lu C, Chu W, Zhang B, Zhen Q, Wang R, et al. MicroRNA-124 suppresses proliferation and glycolysis in non-small cell lung cancer cells by targeting AKT-GLUT1/HKII. Tumor Biol. 2017;39(5):1010428317706215.
16. Han N, Zhao W, Zhang Z, Zhang P. MiR-328 suppresses the survival of esophageal cancer cells by targeting PLCE1. Biochem Biophys Res Commun. 2016;470(1):175–80.
17. Chen C-H, Cheng C-Y, Chen Y-C, Sue Y-M, Liu C-T, Cheng T-H, et al. MicroRNA-328 inhibits renal tubular cell epithelial-to-mesenchymal transition by targeting the CD44 in pressure-induced renal fibrosis. PLoS One. 2014;9(6):e99802.
18. Delic S, Lottmann N, Stelzl A, Liesenberg W, Wolter M, Götz S, et al. MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation. Neuro-Oncology. 2013;16(2):179–90.
19. Li J-R, Wang J-Q, Gong Q, Fang R-H, Guo Y-L. MicroRNA-328 inhibits proliferation of human melanoma cells by targeting TGFβ2. Asian Pac J Cancer Prev. 2015;16:1575–9.
20. Pan Y-Z, Morris ME, Yu A-M. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol. 2009;75(6):1374–9.
21. Li1ABCDE W-Q, Li2ABCDE Y-C, Hu2CDF G-H, Liu1DF H-M et al. Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance. Med Sci Monit. 2010;16(10):30.
22. Monzo M, Santasusanna S, Moreno I, Martinez F, Hernáez R, Muñoz C, et al. Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer. Oncotarget. 2017;8(19):30859.
23. Betel D, Koppal A, Agius P, Sander C, Leslie C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 2010;11(8):R90.
24. Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, Rosenbloom K, et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 2005;15(8):1034–50.
25. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–9.
26. Hauptmann S, Grünwald V, Molls D, Schmitt W, Köbel M, Kriese K, et al. Glucose transporter GLUT1 in colorectal adenocarcinoma cell lines is inversely correlated with tumour cell proliferation. Anticancer Res. 2005;25(5):3431.
27. H-g Xue, A-h Yang, Sun X-g Lu, Y-y Tian Z-b. Expression of microRNA-328 functions as a biomarker for recurrence of early gastric cancer (EGC) after endoscopic submucosal dissection (ESD) by modulating CD44. Med Sci Monit Int Med J Exp Clin Res. 2016;22:4779.
28. Xu XT, Xu Q, Tong JL, Zhu MM, Nie F, Chen X, et al. MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. PLoS One. 2013;10(7):3230–20.
29. Fang MY, Zhou W, Liu L, Alontaga AY, Chandra M, Ashby J, et al. Breast-cancer-secreted mir-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol. 2015;17(2):183–94.
30. Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang W-C, et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 2015;527(7576):100–4.